Literature DB >> 30537730

miR-494 Sensitizes Gastric Cancer Cells to TRAIL Treatment Through Downregulation of Survivin.

Shuning Xu1, Danyang Li1, Tianyuan Li1, Lei Qiao1, Ke Li1, Leiming Guo2, Ying Liu3.   

Abstract

BACKGROUND/AIMS: TNF-related apoptosis-inducing ligand (TRAIL) is a novel and low-toxic anti-tumor drug used for various cancers. However, cancer cells usually develop mechanisms to acquire the resistance against TRAIL. Among these changes, dysregulation of microRNAs (miRNAs) usually occurs in cancer cells and is responsible for induction of drug resistance.
METHODS: Expression of miR-494 in gastric cancer tissues and cell lines was detected by quantitative reverse transcriptase real time PCR (qRT-PCR) analysis. Effect of miR-494 on regulating the TRAIL sensitivity to gastric cancer cell lines was evaluated by MTT assays. Bioinformatics and luciferase reporter assays were used to confirm the regulation of miR-494 on survivin. Mitochondrial apoptosis pathway in gastric cancer cells was tested by western blot and flow cytometry analysis.
RESULTS: Obvious downregulation of miR-494 was observed in gastric cancer cells. Furthermore, we found that expression profile of miR-494 was associated with TRAIL-sensitivity in gastric cancer. Enforced expression of miR-494 was found to sensitize the gastric cancer cells to TRAIL-induced cytotoxicity. Mechanically, Luciferase reporter assays proved that survivin was the target of miR-494 in gastric cancer cells. Enforced expression of miR-494 decreased the expression of survivin, and thus promoted the TRAIL-induced mitochondria collapse and apoptosis pathway.
CONCLUSION: MiR-494/survivin axis represents a potential mechanism which is responsible for TRAIL resistance in gastric cancer cells. Increasing the miR-494 expression may serve as a novel therapeutic strategy to sensitize gastric cancer cells to TRAIL treatment.
© 2018 The Author(s). Published by S. Karger AG, Basel.

Entities:  

Keywords:  Gastric cancer; Survivin; Trail; miR-494

Mesh:

Substances:

Year:  2018        PMID: 30537730     DOI: 10.1159/000495867

Source DB:  PubMed          Journal:  Cell Physiol Biochem        ISSN: 1015-8987


  5 in total

1.  miR-596 suppresses the expression of Survivin and enhances the sensitivity of osteosarcoma cells to the molecular targeting agent anlotinib.

Authors:  Leisheng Wang; He En; Lei Yang; Yanbing Zhang; Baisheng Sun; Jianjiang Gao
Journal:  Onco Targets Ther       Date:  2019-08-21       Impact factor: 4.147

Review 2.  Research Progress in microRNA-Based Therapy for Gastric Cancer.

Authors:  Xu Zhao; Gao-Feng Hu; Yan-Fen Shi; Wei Xu
Journal:  Onco Targets Ther       Date:  2019-12-24       Impact factor: 4.147

3.  Hypoxia induces docetaxel resistance in triple-negative breast cancer via the HIF-1α/miR-494/Survivin signaling pathway.

Authors:  Hongchang Li; Xianhao Sun; Jindong Li; Weiyan Liu; Gaofeng Pan; Anwei Mao; Jiazhe Liu; Qing Zhang; Longhua Rao; Xiaofeng Xie; Xia Sheng
Journal:  Neoplasia       Date:  2022-08-17       Impact factor: 6.218

4.  MicroRNA-494 Regulates Endoplasmic Reticulum Stress in Endothelial Cells.

Authors:  Namita Chatterjee; Eugenia Fraile-Bethencourt; Adrian Baris; Cristina Espinosa-Diez; Sudarshan Anand
Journal:  Front Cell Dev Biol       Date:  2021-07-12

5.  On exosome functional role in cancer: miR-494 complex regulation in melanoma cells and corresponding exosomes.

Authors:  Maria Bellenghi; Giada Pontecorvi; Alessandra Carè
Journal:  Transl Cancer Res       Date:  2019-06       Impact factor: 1.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.